New data from the LEADER trial show that the glucagon-like peptide 1 receptor agonist liraglutide protects against diabetic nephropathy in patients with type 2 diabetes mellitus. The renoprotective efficacy of liraglutide is not, however, as great as that reported for the sodium-glucose cotransporter 2 inhibitor emplagiflozin in the EMPA-REG OUTCOME trial.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat
Cardiovascular Diabetology Open Access 25 March 2019
-
Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm
Diabetes Therapy Open Access 18 August 2018
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Muskiet, M. H. et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat. Rev. Nephrol. 13, 605–628 (2017).
DeFronzo, R. A. et al. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev. Nephrol. 13, 11–26 (2017).
Mann, J. F. et al. Liraglutide and renal outcomes in type 2 diabetes. N. Engl. J. Med. 377, 839–848 (2017).
Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016).
Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016).
Zinman, B. et al. Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk. Stroke 48, 1218–1225 (2017).
Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 12 (2001).
Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 12 (2001).
Hocher, B. Adenosine A1 receptor antagonists in clinical research and development. Kidney Int. 78, 438–445 (2010).
Tsuprykov, O. et al. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy. Kidney Int. 89, 1049–1061 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.H. is a consultant for Boehringer Ingelheim on the development of dipeptidyl peptidase 4 (DPP4) inhibitors and has received research funding from this company for investigation of the renal effects of the DPP4 inhibitor linagliptin. O.T. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Hocher, B., Tsuprykov, O. Renoprotective effects of GLP1R agonists and SGLT2 inhibitors. Nat Rev Nephrol 13, 728–730 (2017). https://doi.org/10.1038/nrneph.2017.140
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2017.140
This article is cited by
-
The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat
Cardiovascular Diabetology (2019)
-
Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm
Diabetes Therapy (2018)